Skip to main content

Advertisement

SpringerLink
Log in

Erythropoietin pharmacology

  • Review
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Anaemia is a frequent complication in cancer patients and may be multifactorial in origin. Treatment with recombinant human erythropoietin (rHuEPO) is an alternative to red blood cell transfusion. The evidence from clinical trials has established that patients with chemotherapy-induced anaemia with a haemoglobin concentration below 10 g/dl benefit from epoetin therapy. The native glycoprotein hormone consists of 165 amino acids with three N-glycosylation and one O-glycosylation sites. Epoetin and darbepoetin bind to the EPO receptor to induce intracellular signalling by the same intracellular molecules as native EPO. There are some differences in the glycosylation pattern which lead to variations in the pharmacokinetics and pharmacodynamics profiles. Pharmacokinetic and therapeutic studies have examined the use of rHuEPO administered intravenously and subcutaneously and there is accumulating evidence that the latter route has several advantages in cancer patients. After subcutaneous administration, the bioavailability of epoetin is about 20–30% and has a plasma half-life of >24 h. Darbepoetin has a longer half-life after subcutaneous administration of 48 h. The general recommendations are based on evidence from trials in which epoetin was administered 150 U/kg thrice weekly. The recommended initial dose for darbepoetin alpha is 2.25 μg/kg per week. The most serious adverse effects are hypertension, bleeding and increased risk of thrombotic complications. Caution is advised when used in patients who are at high risk for thromboembolic events. In the management of anaemic cancer patients, physicians should closely follow the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carnot P, Deflandre C (1906) Sur l’activite hemopoietique de serum au tours de la regeneration du sang. C R Acad Sci Paris 143:384–386

    CAS  Google Scholar 

  2. Ng T, Marx G, Littlewood T et al (2003) Recombinant erythropoietin in clinical practice. Postgrad Med J 79:367–376

    Article  PubMed  CAS  Google Scholar 

  3. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616–1634

    Article  PubMed  CAS  Google Scholar 

  4. Cella D, Kallich J, McDermott A et al (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15:979–986

    Article  PubMed  CAS  Google Scholar 

  5. Bohlius J, Langensiepen S, Schwarzer G et al (2006) Eritropoyetina para los pacientes con enfermedades malignas: La Biblioteca Cochrane Plus, Número 4. Oxford: Update Software Ltd. http://www.update-software.com

    Google Scholar 

  6. Sazama K (1990) Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 30:583–590

    Article  PubMed  CAS  Google Scholar 

  7. Eschbach JW, Abdulhadi MH, Browne JK et al (1989) Recombinant human erythropoietin in anemic patient with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992–1000

    PubMed  CAS  Google Scholar 

  8. Jelkmann W (1992) Erythropoietin: structure, control of production and function. Physiol Rev 72:449–489

    PubMed  CAS  Google Scholar 

  9. Farrell F, Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9[Suppl 5]:18–30

    Article  PubMed  CAS  Google Scholar 

  10. Verdier F, Walrafen P, Hubert N et al (2000) Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 275: 18375–18381

    Article  PubMed  CAS  Google Scholar 

  11. Jelkmann W (2004) Molecular biology of erythropoietin. Intern Med 43:649–656

    Article  PubMed  CAS  Google Scholar 

  12. Priyadarshi A, Shapiro J (2006) Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial 19:273–278

    Article  PubMed  Google Scholar 

  13. Annable L, Cotes PM, Musset MV et al (1972) The second international reference preparation of erythropoietin, human urinary, for bioassay. Bull WHO 47:99–112

    PubMed  CAS  Google Scholar 

  14. Mason Garcia MB, Beckman JW, Brookins JS et al (1990) Development of a new radioimmunoassay for erythropoietin. Kidney Int 38: 969–975

    Article  PubMed  CAS  Google Scholar 

  15. Pérez-Oliva JF, Casanova M, García I et al (2005) Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. BMC Nephrol 6:5

    Article  PubMed  CAS  Google Scholar 

  16. Engert A (2005) Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 16:1584–1595

    Article  PubMed  CAS  Google Scholar 

  17. Egrie JC, Dwyer E, Browne JC et al (2003) Darbepoetin alfa has a longer half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290–299

    Article  PubMed  CAS  Google Scholar 

  18. Sweetman S, Bpharm, MR Pharm S. Martindale A (2004). Guia completa de consulta farmacoterapeútica. Hemoderivados, expansores del plasma y hemostáticos. Epoetinas. 2nd Edición. 1422–1425

  19. Macdougall IC, Gray SJ, Elston O (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392–2395

    PubMed  CAS  Google Scholar 

  20. Macdougall IC, Roberts DE, Neubert P et al (1989) Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 25:425–427

    Article  Google Scholar 

  21. Allon M, Kleinman K, Walczyk M et al (2002) Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 72:546–555

    Article  PubMed  CAS  Google Scholar 

  22. Agoram B, Sutjandra L, Sullivan J et al (2005) Development and evaluation of a population pharmacokinetic (PK) model for darbepoetin alfa in healthy subjects. Clin Pharmacol Ther 77:P76

    Article  Google Scholar 

  23. Heatherington AC, Schuller J, Mercer AJ et al (2001) Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 84[Suppl 1]:11–16

    Article  PubMed  CAS  Google Scholar 

  24. Johnson CA, Wakeen M, Taylor CA et al (1999) Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients. Perit Dial Int 19:578–582

    PubMed  CAS  Google Scholar 

  25. Locatelli F, Canaud B, Giacardy F et al (2003) Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 18:362–369

    Article  PubMed  CAS  Google Scholar 

  26. Littlewood TJ, Bajetta E, Nortier JW et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–2874

    PubMed  CAS  Google Scholar 

  27. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–1220

    PubMed  CAS  Google Scholar 

  28. Cascinu S, Fedeli A, Del Ferro E et al (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12: 1058–1062

    PubMed  CAS  Google Scholar 

  29. Österborg A, Boogaerts MA, Cimino R et al (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma-a randomized multicenter study. Blood 87:2675–2682

    PubMed  Google Scholar 

  30. Del Mastro L, Venturini M, Lionetto R et al (1997) Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715–2721

    PubMed  Google Scholar 

  31. Seidenfeld J, Piper M, Flamm C et al (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and metaanalysis of controlled clinical trials. J Natl Cancer Inst 93:1204–1214

    Article  PubMed  CAS  Google Scholar 

  32. Glaspy J, Bukowsky R, Steinberg D et al (1997) Impact of therapy with Epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218–1234

    PubMed  CAS  Google Scholar 

  33. Gabrilove JL, Cleeland CS, Livingston RB et al (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875–2882

    PubMed  CAS  Google Scholar 

  34. Glaspy JA, Jadeja JS, Justice G (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87:268–276

    Article  PubMed  CAS  Google Scholar 

  35. Kotasek D, Steger G, Faught W et al (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39:2026–2034

    Article  PubMed  CAS  Google Scholar 

  36. Bocciaa R, Malikb IA, Rajac V et al (2006) Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 11:409–417

    Article  Google Scholar 

  37. Hesketh PJ, Arena F, Patel D et al (2004) A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 100:859–868

    Article  PubMed  CAS  Google Scholar 

  38. Canon J, Vansteenkiste J, Bodoky G et al (2006) Randomized double-blind, active controlled trial of every-3-week darbepoetin alfa for the treatment to chemotherapy induced anemia. J Natl Cancer Inst 98:273–284

    Article  PubMed  CAS  Google Scholar 

  39. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guide-lines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083–4107

    Article  PubMed  CAS  Google Scholar 

  40. Thames WA, Smith SL, Scheifele AC et al (2004) Evaluation of the US Oncology Networks recommended guidelines for therapeutic substitution with darbepoetin alfa 200 mcg every 2 weeks in both naïve patients and patients switched from epoetin alfa. Pharmacotherapy 24: 313–323

    Article  PubMed  CAS  Google Scholar 

  41. Goram AL (2006) Every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia. Am J Health Syst Pharm 63:1522–1527

    Article  PubMed  CAS  Google Scholar 

  42. Peeters HR, Jongen-Lavrencic M, Bakkar CH et al (1999) Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 18: 201–206

    Article  PubMed  CAS  Google Scholar 

  43. Wurnig C, Schatz K, Noske H et al (2001) Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res 33:303–310

    Article  PubMed  CAS  Google Scholar 

  44. Van Iperen CE, Gaillard CA, Kraaijenhagen RJ et al (2000) Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 28:2773–2778

    Article  PubMed  Google Scholar 

  45. Ekblom BT (2000) Blood boosting and sport. Baillieres Clin Endocrinol Metab 14:89–98

    Article  CAS  Google Scholar 

  46. Bohlius J, Wison J, Seidenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714

    PubMed  CAS  Google Scholar 

  47. Zhu X, Perazella M (2006) Nonhematologic complications of erythropoietin therapy. Semin Dial 19:279–284

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital Clínico Universitario Virgen de La Victoria, C/ Campus de Teatinos, s/n, ES-29010, Málaga, Spain

    J. M. Jurado García, E. Torres Sánchez, D. Olmos Hidalgo & E. Alba Conejo

Authors
  1. J. M. Jurado García
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Torres Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Olmos Hidalgo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Alba Conejo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. M. Jurado García.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jurado García, J.M., Torres Sánchez, E., Olmos Hidalgo, D. et al. Erythropoietin pharmacology. Clin Transl Oncol 9, 715–722 (2007). https://doi.org/10.1007/s12094-007-0128-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0128-y

Key words Cancer

Search

Navigation